What is HC Wainwright’s Estimate for BDTX Q3 Earnings?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Stock analysts at HC Wainwright issued their Q3 2025 earnings estimates for shares of Black Diamond Therapeutics in a research note issued to investors on Monday, August 11th. HC Wainwright analyst R. Burns expects that the company will earn ($0.24) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at $0.33 EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.26) EPS and Q4 2026 earnings at ($0.27) EPS.

A number of other research analysts have also recently issued reports on the stock. Wall Street Zen cut shares of Black Diamond Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Raymond James Financial raised shares of Black Diamond Therapeutics to an “outperform” rating and set a $11.00 price target for the company in a research report on Tuesday, July 1st. Finally, Zacks Research raised shares of Black Diamond Therapeutics to a “strong-buy” rating in a research report on Monday, August 11th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Black Diamond Therapeutics currently has an average rating of “Buy” and an average target price of $12.40.

Black Diamond Therapeutics Trading Down 1.1%

NASDAQ:BDTX opened at $2.76 on Thursday. The company has a 50-day moving average price of $2.65 and a 200-day moving average price of $2.15. Black Diamond Therapeutics has a 12 month low of $1.20 and a 12 month high of $6.75. The stock has a market cap of $157.15 million, a price-to-earnings ratio of 12.00 and a beta of 2.87.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its earnings results on Thursday, August 7th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.06.

Institutional Investors Weigh In On Black Diamond Therapeutics

Large investors have recently bought and sold shares of the business. R Squared Ltd purchased a new stake in Black Diamond Therapeutics in the second quarter worth about $25,000. Cerity Partners LLC purchased a new stake in Black Diamond Therapeutics in the second quarter worth about $26,000. Hudson Bay Capital Management LP purchased a new stake in Black Diamond Therapeutics in the second quarter worth about $26,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Black Diamond Therapeutics in the second quarter worth about $28,000. Finally, American Century Companies Inc. purchased a new stake in Black Diamond Therapeutics in the second quarter worth about $30,000. Institutional investors own 95.47% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.